Cargando…
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
SIMPLE SUMMARY: Epithelial-to-mesenchymal transition (EMT) is a cellular plasticity program that can confer invasiveness, dissemination, and therapy resistance to cancer cells. Although inhibitors of this cellular process are expected to work as good “partners” for chemotherapy, immunotherapy or tar...
Autores principales: | Verdura, Sara, Encinar, Jose Antonio, Teixidor, Eduard, Segura-Carretero, Antonio, Micol, Vicente, Cuyàs, Elisabet, Bosch-Barrera, Joaquim, Menendez, Javier A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777025/ https://www.ncbi.nlm.nih.gov/pubmed/36551587 http://dx.doi.org/10.3390/cancers14246101 |
Ejemplares similares
-
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022) -
Lung Cancer Management with Silibinin: A Historical and Translational Perspective
por: Verdura, Sara, et al.
Publicado: (2021) -
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
por: Cufí, Sílvia, et al.
Publicado: (2013) -
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021) -
Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers
por: Pérez-Sánchez, Almudena, et al.
Publicado: (2019)